Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $55 to $50.
Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $55 to $50.